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Abstract
Immunofluorescence microscopy of the skin has disclosed antibodies bound to epidermal cell nuclei in several connective tissue disorders. To establish the diagnostic potential of this phenomenon the results of immunofluorescence microscopy of biopsy specimens from 1651 subjects with various diseases and from 315 patients with systemic connective tissue disorders and related diseases were reviewed. It was found that the predictive value of the phenomenon for the presence of a systemic connective tissue disorder was, in general, 88%. Except for the homogeneous and thready patterns, which seldom appear, but are specific for SLE, in vivo antinuclear antibody (ANA) does not discriminate better between the various disorders than do serum antibodies. The presence of in vivo ANA in the skin was related to serum antibodies against non-histone nucleoproteins, but not to anti-dsDNA antibodies. Combined with the finding that antibodies against non-histone nucleoproteins can bind on the surface of human keratinocytes, this suggests that ANA of the skin occurs in vivo.
Antinuclear antibodies (ANAs) are commonly found in the blood of patients with systemic connective tissue disorders (SCTDs)-that is, systemic lupus erythematosus (SLE), scleroderma, dermatomyositis/polymyositis, Sjogren's syndrome, mixed connective tissue disease, and rheumatoid arthritis. Immunofluorescence microscopy of skin biopsy specimens from both clinically involved and uninvolved skin in these disorders has shown antibodies bound to epidermal cell nuclei (in vivo ANA of the skin)."10 In most disorders the prevalence of the phenomenon has not been investigated systematically, whereas in others-for example, SLE, the results vary widely (table 1). The (14) 8 (13) 0 (8) 0 (8) 0 (7) 8 (12) 8 (12) MCTD* 100 (6) 100 (6) ¶ 100 (6) 0 (6) 0 (6) 0 (6) 100 (6) 33 (6) Overlap syndrome4
71 (17) 1159 (17) 62 (13) 40 (10) 33 (9) 0 (12) 33 (9) 19 (16) Wegener's disease and periarteritis nodosa 0 80 (15) 1161 (13) 66 (9) 100 (3) 20 (5) 0 (5) 50 (8) (82) 29 (51) 38 (21) 13 (40) 17 (41) 20 (41) 35 (49) Sj6gren's syndrome Primary 65 (20) 1145 (16) 60 (15) 66 (15) 60 (15) 0 (16) 8 (12) 0 (12) Secondary4 60 (10) 50 (8) 50 (6) 20 (5) 40 (5) 0 (7) 50 (6) 62 (8) *ANA=antinuclear antibody; ENA=extractable nuclear antigen; MCTD=mixed connective tissue disease.
tEight patients are also included under the diagnosis systemic lupus erythematosus. tThese patients are also included in another diagnostic group.
SFisher's test biased by a large number of negative test results.
IIStatistically significant association between in vivo ANA and serum ANA. ¶No statistical test possible because no positive or negative reactions were found. (fig 2) . In general, speckled ANA patterns were found significantly more often in skin than in serum, whereas the homogeneous pattern was found more commonly in serum than in skin. This may be the result of incomplete dilution of the serum, of the difference in the tissues involved (human skin and mouse liver), or of differences in interpretation of the immunofluorescence patterns.
Both in lupus erythematosus and in the other SCTDs the presence of in vivo ANA of the skin was associated with antibodies against nonhistone nucleoproteins-that is, SSA, SSB, RNP, Sm, but not with antibodies against dsDNA. As antibodies against both dsDNA and non-histone nucleoproteins can bind to epidermal cell nuclei in sections of human skin, such an association cannot be explained if the 'in vivo ANA' phenomenon has been caused by passive diffusion-for example, during incubation of the sections. Therefore we concluded that the deposition of antibodies in epidermal cell nuclei is at least partly controlled by a mechanism that selects for antibodies against non-histone nucleoproteins and against antidsDNA antibodies.
The greatest barrier for the in vivo binding of an antibody to the keratinocyte nucleus is the epidermal cell membrane. Antibodies are not able to permeate the membrane of vital keratinocytes by simple diffusion. " 16 In studies on the binding of antibodies on the cell surface of' keratinocytes in suspensions and in culture it was found that antibodies against non-histone nucleoproteins did bind, whereas antibodies against dsDNA did not." 12 This suggests that selective binding of antibodies against nonhistone nucleoproteins on the cell surface, followed by active incorporation of the bound antibody, controls the formation of in vivo ANA in the skin.
Conclusion
The presence of in vivo ANA in the clinically healthy skin is a phenomenon with a high predictive value for a systemic connective tissue disorder. Its diagnostic value in discriminating between the various SCTDs is low, however, compared with serum antibodies. This does not eliminate the use of immunofluorescence microscopy in SCTD as staining at the basal membrane zone was not included in this study. The selective association between in vivo ANA in the skin and non-histone nucleoprotein antibodies in the blood suggests that we are dealing with a phenomenon occurring in vivo.
